$PPCB

$0.68▲ +7.9% YTD

3 SEC 13D/G filings tracked · Last updated Sep 22, 2026

Filing History

CP $0.68▲ +7.9%Sep 22, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015…

News

PPCB ▼ -1.0% - Propanc Biopharma, Inc.

CP $1.00▲ -1.0%Sep 9, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027…

News

PPCB ▲ +177.6% - Propanc Biopharma, Inc.

CP 2.97▲ +177.6%Aug 27, 2026 · ThinkSabio Blog

$PPCB Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Surviva…